Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL

29 Jan 2020

Abstract excerpt

The Bruton tyrosine kinase (BTK) inhibitor ibrutinib provides effective treatment for patients with chronic lymphocytic leukemia (CLL), despite extensive heterogeneity in this disease. To define the underlining regulatory dynamics, we analyze high-resolution time courses of ibrutinib treatment in patients with CLL, combining immune-phenotyping, single-cell transcriptome profiling, and chromatin mapping. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Immunodeficiency and Autoimmune Disorders
Share to Single-cell and spatial transcriptomics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31996669
DOI: 10.1038/s41467-019-14081-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLLPMID 31996669Read ↗

Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib drug response in chronic lymphocytic leukemiaSemantic proximity Read ↗

Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib.Semantic proximity Read ↗

Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapseSemantic proximity Read ↗

Defining the BTK-dependent chromatin-informed gene regulatory network in chronic lymphocytic leukemiaSemantic proximity Read ↗

Epigenomic evolution in chronic lymphocytic leukaemia cells from patients treated with ibrutinib and showing disease progressionSemantic proximity Read ↗

Constitutive Activation of the B Cell Receptor Underlies Dysfunctional Signaling in Chronic Lymphocytic LeukemiaSemantic proximity Read ↗

Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphomaSemantic proximity Read ↗

Single-cell Transcriptome Analysis Uncovers Heterogeneity and Key Regulators in Ibrutinib-resistant Chronic Lymphocytic LeukemiaSemantic proximity Read ↗

Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia.Semantic proximity Read ↗

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.Semantic proximity Read ↗

Leukemia core transcriptional circuitry is a sparsely interconnected hierarchy stabilized by incoherent feed-forward loopsSemantic proximity Read ↗

Single-Cell RNA-seq Reveals LGALS1 and LAG3 as Novel Drivers of Ibrutinib Resistance in Chronic Lymphocytic LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.